AI Drug Design Startup Boltz Closes Multi-Investor Funding Round
AI drug design startup Boltz announced a new funding round with backing from Bessemer, a16z, Amplify Partners and others. The company says its next-generation models significantly improve generated molecule quality, with a long-term goal of going from hypothesis to human-ready molecules entirely in silico.
2026-11-18 ~ 2026-11-18 · 2 related posts
- Boltz's long-term goal: hypothesis to human-ready molecule without leaving the computer — GabriCorso · 2026-11-18
- Boltz, backed by a16z and Bessemer, aims to take drug hypotheses to human-ready molecules on a computer — GabriCorso · 2026-11-18